Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.6587
- Book/Share 2.3783
- PB 1.1227
- Debt/Equity 0.07
- CurrentRatio 4.1783
- ROIC -0.4632
- MktCap 891603780.0
- FreeCF/Share -1.0763
- PFCF -2.5658
- PE -2.2966
- Debt/Assets 0.0556
- DivYield 0
- ROE -0.4971
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | Goldman | Neutral | Sell | -- | $1 | July 15, 2025 |
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
The Gross Law Firm Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline
Published: June 05, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151693&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
Read More
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, June 04, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 14, 2025 Deadline
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151686&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT: Iovance Biotherapeutics, Inc. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Shareholders of Iovance Biotherapeutics, Inc. Should Contact The Gross Law Firm Before July 14, 2025 to Discuss Your Rights – IOVA
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
Read More
Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151644&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
IOVA ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. - July 14, 2025 Deadline
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151624&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Published: June 04, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , June 4, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" …
Read More
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 14, 2025 Deadline
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151607&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT NOTICE: Lose Money on Iovance Biotherapeutics, Inc.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NASDAQ:IOVA)
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
IOVA STOCK NOTICE: Iovance Biotherapeutics, Inc. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 14 Legal Deadline
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
IOVA ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Iovance Biotherapeutics, Inc. - July 14, 2025 Deadline
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151493&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151468&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
Securities Fraud Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - Levi & Korsinsky Reminds Investors of July 14, 2025
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151448&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151409&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.
Read More
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors - Contact Levi & Korsinsky Before July 14, 2025
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151393&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq.
Read More
IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Iovance Biotherapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ:IOVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151376&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Read More
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY AND NEW ORLEANS, LA / ACCESS Newswire / June 2, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NasdaqGM:IOVA), if they purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period").
Read More
Iovance Biotherapeutics, Inc. (IOVA) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 14, 2025
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151360&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"), of the important July 14, 2025 lead plaintiff deadline. So What: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit And July 14, 2025 Deadline
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151349&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Read More
IOVA Stock News: Stockholders with Significant Losses Should Contact Shareholder Rights Law Firm Robbins LLP for Information About the Class Action Lawsuit Against Iovance Biotherapeutics, Inc.
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , June 2, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers.
Read More
IOVA STOCK ALERT: Iovance Biotherapeutics, Inc. Shareholders With Losses May Have Been Affected by Fraud - Contact BFA Law
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151297&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151284&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
Scott+Scott Attorneys at Law LLP Continues to Remind Investors There is a Securities Class Action Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. …
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Frederick G. Vogt
- Employees 838